Cover Story
FreeNews Analysis
By Matthew Bin Han Ong
Now that Joseph R. Biden Jr. is inaugurated and safely ensconced in the White House, cancer groups expect him to pick up where he left off as vice president four years ago—pursuing a sober and ambitious agenda for accelerating progress in cancer research.
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
Trending Stories
- As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research - Trump 2016: A look back at the 45th president’s impact on oncology
- When cigarette filters were made of asbestos
- Cedars-Sinai spearheads first national certification program for COE staff at cancer centers
- Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- Patient navigation benefits health systems, improves care
Initial data presented at the White House come a year after CMS payment began